PASSAGE BIO INC

PASG represents Passage Bio, a clinical-stage biotechnology company focused on developing gene therapies for rare and devastating monogenic central nervous system disorders. Its pipeline targets conditions such as frontotemporal dementia, Krabbe disease, and metachromatic leukodystrophy. As a clinical-stage company, its activities center on research, preclinical studies, and clinical trials rather than marketed products.

The latest price of PASG stock is displayed in real time on this page and can fluctuate throughout each trading session. Because prices change constantly, the most reliable source for the current quote is the live data shown here. Reviewing the bid, ask, and most recent trade can help you understand where PASG is currently trading.

PASG stock may experience significant price swings because it is a clinical-stage biotechnology company whose value often hinges on trial data, regulatory news, and financing developments. Small-cap biotech shares frequently trade with wider daily percentage moves than large diversified companies. Historical volatility can be reviewed using the price chart and performance data available on this page.

Evaluating PASG's valuation is unconventional because the company is clinical-stage and may not generate meaningful revenue or earnings. Traditional metrics like P/E ratios often are not applicable, so investors may examine cash balances, research and development spending, pipeline progress, and potential market opportunities for its gene therapies instead. Any valuation figures should be checked against the latest PASG data displayed on this page.

PASG may be available for trading in pre-market and after-hours sessions through certain brokers, though liquidity is typically lower and spreads can be wider than during regular market hours. Not all brokerage platforms support extended-hours trading for every stock. Check with your broker and review the trading information on this page for specific availability and session details.

Key risks include clinical trial failure, regulatory delays, and the need for additional capital, which can dilute existing shareholders. As a preclinical and clinical-stage gene therapy company, PASG faces scientific, manufacturing, and competitive risks, and its stock price may be highly sensitive to news. Investors should review the company's latest filings and the risk factors disclosed in its SEC reports.